- Home
- BBUC vs SYRE Comparison
BBUC vs SYRE Comparison
Compare BBUC & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BBUC | SYRE |
|---|---|---|
| Founded | 2022 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.6B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | BBUC | SYRE |
|---|---|---|
| Price | $36.74 | $33.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $56.50 |
| AVG Volume (30 Days) | 92.4K | ★ 795.0K |
| Earning Date | 01-30-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.69% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,713,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $21.52 | $10.91 |
| 52 Week High | $37.89 | $35.31 |
Technical Indicators
Market Signals| Indicator | BBUC | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 55.12 | 58.08 |
| Support Level | $34.80 | $30.00 |
| Resistance Level | $35.79 | $34.21 |
| Average True Range (ATR) | 1.21 | 1.83 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 69.98 | 84.46 |
Price Performance
Historical ComparisonAbout BBUC Brookfield Business Corporation Exchangeable Subordinate Voting Shares
Brookfield Business Corp is a company established as a vehicle that owns and operates certain services and industrial operations on a world-wide basis and an alternative vehicle for investors who prefer investing in its operations through a corporate structure. Its goal is to generate returns through long-term capital appreciation with a modest distribution yield.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.